Business Context and Reporting Period
Company: Sunshine Biopharma Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 30, 2019
Event Date: June 30, 2019
Status: Emerging Growth Company
This filing reports the termination of a material definitive agreement regarding a share purchase and associated promissory note with Mohamed Belhaj.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. Specific financial details disclosed relate to a terminated debt obligation:
- Promissory Note Principal: $450,000 CAD (approx. $346,000 USD).
- Quarterly Payment Obligation: $10,000 CAD (approx. $7,700 USD).
- Collateral: All issued and outstanding shares of Atlas Pharma Inc.
- Intercompany Loans: All loans between Sunshine Biopharma and Atlas Pharma were cancelled.
Material Changes
On June 30, 2019, the company informed the counterparty of its inability to make the scheduled payment on the Promissory Note and its inability to make future payments. Consequently:
- The company agreed to assign the shares of Atlas Pharma Inc. back to Mohamed Belhaj.
- The Promissory Note and all obligations thereunder were cancelled in exchange for the share return.
- All intercompany loans and obligations arising from the relationship were released.
Outlook, Risks, and Management Commentary
Management Commentary: The company explicitly stated it was unable to meet its payment obligations under the Promissory Note due on June 30, 2019, and did not believe it could make subsequent payments.
Risks and Contingencies: The filing highlights a liquidity constraint preventing debt service. The resolution involved the loss of the Atlas Pharma Inc. asset (shares) to satisfy the debt obligation.
Investor Verification Checklist
- Verify the current ownership status of Atlas Pharma Inc. shares following the transfer back to Mohamed Belhaj.
- Confirm the total outstanding debt and liquidity position of Sunshine Biopharma Inc. post-cancellation.
- Review the impact of losing the Atlas Pharma Inc. asset on the company's future business strategy and revenue pipeline.
- Check for any other undisclosed defaults or payment failures on other obligations.